



IMAGES IN PAEDIATRICS

Lipomatosis epidural secundaria a corticoterapia

Epidural lipomatosis secondary to corticotherapy



Marina Mora Sitja^{a,*}, Jorge Huerta Aragonés^b, María Sanz Fernández^a,
Carmen Garrido Colino^b

^a Sección Endocrinología Pediátrica, Hospital General Universitario Gregorio Marañón, Madrid, Spain

^b Sección Hematología y Oncología Hospital General Universitario Gregorio Marañón, Madrid, Spain

Received 12 August 2022; accepted 2 November 2022

Available online 28 April 2023

A male patient aged 15 years who had received a diagnosis of Evans syndrome required prolonged treatment with prednisone (2 mg/kg/day for 4 weeks, followed by a dose of 1 mg/kg/day that could not be reduced due to recurrence). At 3 months of treatment, he started experiencing intense, activity-limiting lumbar pain unresponsive to analgesia, progressive, radiating from the lower extremities and decreased proximal strength (4/5). The patient was admitted for evaluation and pain management. A magnetic resonance imaging (MRI) scan of the spine evinced extensive spinal epidural lipomatosis (Fig. 1) secondary to the treatment.

Conservative treatment with analgesia and rehabilitation was initiated at the same time as mycophenolate mofetil for treatment of Evans syndrome with the aim of tapering off the steroid, which was withdrawn completely 3 months after the diagnosis of lipomatosis without any complications. The patient had a favourable outcome.

Spinal epidural lipomatosis is characterised by an overgrowth of fatty tissue in the epidural sac in the spinal canal that can cause progressive compression of the spinal




Figure 1 Magnetic resonance of the spine evincing an increase in epidural fat (spinal epidural lipomatosis) resulting in stenosis of the spinal canal at the dorsal (1A) and lumbar (1B) levels. The mass effect was most severe in the L4-S1 segment (1B) and possibly compounded by congenital lumbar canal stenosis.

cord. Steroid therapy has been described as its most common cause^{1,2}, and while spinal epidural lipomatosis is a rare adverse event, it should be suspected in patients presenting with compatible symptoms (lumbar pain,

* Corresponding author.

E-mail address: marina.mora@salud.madrid.org (M. Mora Sitja).

pain and loss of strength in lower extremities). Magnetic resonance is the gold standard of diagnosis³ and the first-line treatment is conservative—with some patients requiring surgical decompression²—with withdrawal of the steroid whenever possible.

Funding

This research did not receive any external funding.

Conflicts of interest

The authors have no conflicts of interest to declare.

References

1. Möller JC, Cron RQ, Young DW, Girschick HJ, Levy DM, Sherry DD, et al. Corticosteroid-induced spinal epidural lipomatosis in the pediatric age group: report of a new case and updated analysis of the literature. *Pediatr Rheumatol Online J*. 2011;9:5, <http://dx.doi.org/10.1186/1546-0096-9-5>.
2. Walker PB, Sark C, Brennan G, Smith T, Sherman WF, Kaye AD. Spinal Epidural Lipomatosis: A Comprehensive Review. *Orthop Rev (Pavia)*. 2021;13:25571, <http://dx.doi.org/10.52965/001c.25571>.
3. Muñoz A, Barkovich JA, Mateos F, Simón R. Symptomatic epidural lipomatosis of the spinal cord in a child: MR demonstration of spinal cord injury. *Pediatr Radiol*. 2002;32:865–8.